TY - JOUR
T1 - Tumor-Agnostic Precision Medicine from the AACR GENIE Database
T2 - Clinical Implications
AU - Gouda, Mohamed A.
AU - Nelson, Blessie E.
AU - Buschhorn, Lars
AU - Wahida, Adam
AU - Subbiah, Vivek
N1 - Publisher Copyright:
©2023 The Authors; Published by the American Association for Cancer Research.
PY - 2023/8/1
Y1 - 2023/8/1
N2 - Biomarker-driven cancer therapy has revolutionized precision oncology. With a better understanding of tumor biology, tissueagnostic targets have been characterized and explored, which ultimately led to therapeutics with pan-cancer efficacy. To date, five molecular biomarkers have obtained FDA tissue-agnostic approval for targeted therapies and immunotherapies. Those include BRAFV600E mutations, RET fusions, NTRK fusions, high tumor mutation burden (TMB), and deficient mismatch repair/ high microsatellite instability (dMMR/MSI-High). Herein, we have used data from AACR project GENIE to explore the clinicogenomic landscape of these alterations. AACR GENIE is a publicly accessible registry of genomic data from multiple collaborating cancer centers. Current database (version 13.0) includes sequencing data of 168,423 samples collected from patients with different cancers. We were able to identify BRAFV600E, RET fusions, NTRK fusions, and high TMB in 2.9%, 1.6%, 1.5%, and 15.2% of pan-cancer samples, respectively. In this article, we describe the distribution of those tissue-agnostic targets among different cancer types. In addition, we summarize the current prospect on the biology of these alterations and evidence on approved drugs, including pembrolizumab, dostarilmab, larotrectinib, entrectinib, selpercatinib, and dabrafenib/trametinib combination.
AB - Biomarker-driven cancer therapy has revolutionized precision oncology. With a better understanding of tumor biology, tissueagnostic targets have been characterized and explored, which ultimately led to therapeutics with pan-cancer efficacy. To date, five molecular biomarkers have obtained FDA tissue-agnostic approval for targeted therapies and immunotherapies. Those include BRAFV600E mutations, RET fusions, NTRK fusions, high tumor mutation burden (TMB), and deficient mismatch repair/ high microsatellite instability (dMMR/MSI-High). Herein, we have used data from AACR project GENIE to explore the clinicogenomic landscape of these alterations. AACR GENIE is a publicly accessible registry of genomic data from multiple collaborating cancer centers. Current database (version 13.0) includes sequencing data of 168,423 samples collected from patients with different cancers. We were able to identify BRAFV600E, RET fusions, NTRK fusions, and high TMB in 2.9%, 1.6%, 1.5%, and 15.2% of pan-cancer samples, respectively. In this article, we describe the distribution of those tissue-agnostic targets among different cancer types. In addition, we summarize the current prospect on the biology of these alterations and evidence on approved drugs, including pembrolizumab, dostarilmab, larotrectinib, entrectinib, selpercatinib, and dabrafenib/trametinib combination.
UR - http://www.scopus.com/inward/record.url?scp=85163481406&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85163481406&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-23-0090
DO - 10.1158/1078-0432.CCR-23-0090
M3 - Review article
C2 - 37061987
AN - SCOPUS:85163481406
SN - 1078-0432
VL - 29
SP - 2753
EP - 2760
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 15
ER -